0.06%
-3.31%
7.98%
64.43%
111.24%
77.54%
-22.21%
AI Spotlight on CNTA
Company Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients.Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1.
In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases.Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Market Data
| Last Price | 16.92 |
| Change Percentage | 0.06% |
| Open | 16.97 |
| Previous Close | 16.91 |
| Market Cap ( Millions) | 2228 |
| Volume | 728644 |
| Year High | 18.97 |
| Year Low | 7.38 |
| M A 50 | 16.81 |
| M A 200 | 13.17 |
Financial Ratios
| FCF Yield | -5.85% |
| Dividend Yield | 0.00% |
| ROE | -52.22% |
| Debt / Equity | 16.97% |
| Net Debt / EBIDTA | 210.38% |
| Price To Book | 3.94 |
| Price Earnings Ratio | -12.17 |
| Price To FCF | -17.08 |
| Price To sales | 322.26 |
| EV / EBITDA | -13.0 |
News
- Jan -08 - Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
- Dec -26 - Centessa: Shift In Focus With ORX750 Development Continues To Pay Off
- Nov -12 - Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
- Sep -28 - Wake Up to This Biotech Stock That Still Has Big Potential Upside
- Sep -26 - Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
- Sep -13 - Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
- Sep -11 - Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
- Sep -10 - Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
- Aug -27 - Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
- Aug -21 - Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Aug -13 - Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
- Jul -16 - Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade
- Jun -10 - Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
- May -28 - Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)
- May -21 - Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- May -13 - Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
- Apr -24 - Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
- Apr -24 - Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
- Apr -22 - Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
- Mar -28 - Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceutical
Expected Growth : 9.27 %
What the company do ?
Centessa Pharmaceuticals plc is a pharmaceutical company focused on developing and commercializing life-changing medicines for patients with high unmet medical needs.
Why we expect these perspectives ?
Centessa Pharmaceuticals plc's 9.27% growth is driven by increasing demand for rare disease treatments, strategic partnerships, and a strong pipeline of novel therapies. The company's focus on gene therapy and small molecule development also contributes to its growth, as well as its ability to leverage its platform to identify and acquire promising assets.
Centessa Pharmaceuticals Plc Products
| Product Range | What is it ? |
|---|---|
| CX-102 | CX-102 is a novel, oral, small molecule inhibitor of serine/threonine kinase 1 (STK11) for the treatment of solid tumors. |
| CX-202 | CX-202 is a novel, oral, small molecule inhibitor of cyclin-dependent kinase 2/4/6 (CDK2/4/6) for the treatment of breast cancer and other solid tumors. |
| CX-205 | CX-205 is a novel, oral, small molecule inhibitor of fibroblast growth factor receptor 1-3 (FGFR1-3) for the treatment of solid tumors. |
| CX-611 | CX-611 is a novel, oral, small molecule inhibitor of bromodomain and extra-terminal motif (BET) for the treatment of hematological malignancies. |
Centessa Pharmaceuticals plc's Porter Forces
Threat Of Substitutes
Centessa Pharmaceuticals plc has a moderate threat of substitutes due to the availability of alternative treatments and therapies for the diseases it targets.
Bargaining Power Of Customers
Centessa Pharmaceuticals plc has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative options for patients.
Bargaining Power Of Suppliers
Centessa Pharmaceuticals plc has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and the company's dependence on a few key suppliers.
Threat Of New Entrants
Centessa Pharmaceuticals plc has a high threat of new entrants due to the growing demand for pharmaceuticals and the increasing number of biotech startups entering the market.
Intensity Of Rivalry
Centessa Pharmaceuticals plc operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 24.27% |
| Debt Cost | 11.19% |
| Equity Weight | 75.73% |
| Equity Cost | 11.19% |
| WACC | 11.19% |
| Leverage | 32.04% |
Centessa Pharmaceuticals plc : Quality Control
Centessa Pharmaceuticals plc passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CALTX.ST | Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It … |
| IDIA.SW | Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, … |
| ATRY.MC | Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second … |
| NAMS | NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets … |
| FYB.DE | Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Calliditas Therapeutics
A-Score
1-Year Total Return ->
🥈
Centessa Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
Formycon
A-Score
1-Year Total Return ->
4
NewAmsterdam Pharma
A-Score
1-Year Total Return ->
5
Atrys Health
A-Score
1-Year Total Return ->
6
